Chugai (4519.T) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Chugai, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track 4519.T live on Mooboard →
Later1
- Jun 15, 2027ClinicalTrials.gov ↗Chugai(4519.T)Phase 2/3 readoutPlacebo DONQ52 · Phase 2 · Celiac DiseaseNCT07239336: Study of DONQ52 in Active Celiac Disease. Primary completion 2027-06-15 (estimated); status RECRUITING.
How Chugai has moved — past-year price reactions
How binary is 4519.T? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
- -15.8%2026-04-27no matched headline
- -8.1%2026-03-23no matched headline
- -7.7%2026-07-27no matched headline
- +7.4%2025-11-07no matched headline
- +6.6%2026-04-28no matched headline
- -6.5%2026-05-26no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Chugai — active clinical pipeline
Chugai's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
See the full biopharma catalyst calendar across all covered companies.